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Abstract
EFSA was asked by the European Commission to deliver a scientiﬁc opinion on the risks for human
health related to the presence of pyrrolizidine alkaloids (PAs) in honey, tea, herbal infusions and food
supplements and to identify the PAs of relevance in the aforementioned food commodities and in other
feed and food. PAs are a large group of toxins produced by different plant species. In 2011, the EFSA
Panel on Contaminants in the Food Chain (CONTAM Panel) assessed the risks related to the presence
of PAs in food and feed. Based on occurrence data limited to honey, the CONTAM Panel concluded that
there was a possible health concern for those toddlers and children who are high consumers of honey.
A new exposure assessment including new occurrence data was published by EFSA in 2016 and was
used to update the risk characterisation. The CONTAM Panel established a new Reference Point of
237 lg/kg body weight per day to assess the carcinogenic risks of PAs, and concluded that there is a
possible concern for human health related to the exposure to PAs, in particular for frequent and high
consumers of tea and herbal infusions. The Panel noted that consumption of food supplements based
on PA-producing plants could result in exposure levels causing acute/short-term toxicity. From the
analysis of the available occurrence data, the CONTAM Panel identiﬁed a list of 17 PAs of relevance for
monitoring in food and feed. The Panel recommended continuing the efforts to monitor the presence
of PAs in food and feed, including the development of more sensitive and speciﬁc analytical methods.
A recommendation was also issued on the generation of data to identify the toxic and carcinogenic
potency of the PAs commonly found in food.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
The EFSA Panel on Contaminants in the Food Chain (CONTAM) adopted in 2011 a scientiﬁc opinion
on pyrrolizidine alkaloids in food and feed.1
In this scientiﬁc opinion, the CONTAM Panel performed estimates of both acute and chronic
exposure to pyrrolizidine alkaloids through honey. Due to lack of data on the presence of pyrrolizidine
alkaloids (PAs) in foods other than honey, the CONTAM Panel was not able to quantify dietary
exposure from food other than honey. A number of PAs of particular importance for food and feed
were identiﬁed and recommended to be included in future monitoring of the presence of PAs feed and
food. The CONTAM Panel concluded that 1,2-unsaturated PAs may act as genotoxic carcinogens in
humans. Therefore, the CONTAM Panel decided to apply the Margin of Exposure (MOE) approach. A
benchmark dose lower conﬁdence limit for a 10% excess cancer risk (BMDL10) of 70 lg/kg body
weight (bw) per day was calculated as the reference point (RP) for comparison with the estimated
dietary exposure. The CONTAM Panel concluded that there is a possible health concern for those
toddlers and children who are high consumers of honey.
It was furthermore concluded that, although no occurrence data were available, exposure to PAs
from pollen, tea, herbal infusions and herbal dietary supplements could potentially present a risk of
both acute and chronic effects in the consumer.
Following the outcome of this scientiﬁc opinion from the CONTAM Panel on PAs in food and feed
and the availability of new occurrence data on the presence of PAs in food, the Commission requested
EFSA for a dietary exposure assessment to PAs in honey, tea, herbal infusions (herbs) and food
supplements.
Following this request, EFSA approved on 13 July 2016 a scientiﬁc report on the ‘Dietary exposure
to PAs in the European population’.2
Chronic and acute dietary exposure to PAs was estimated in the European population via the
consumption of plant-derived foods. This resulted in highest estimates of mean chronic dietary
exposure of 34.5–48.4 ng/kg bw per day in ‘Toddlers’ (LB–UB3 ) and 154–214 ng/kg bw per day in the
highly exposed population (LB–UB, also in ‘Toddlers’). Following a rather conservative scenario, the
highest estimates of acute mean exposure and 95th percentile exposure were calculated for ‘Toddlers’,
with mean exposure up to 311 ng/kg bw per day and 95th percentile exposure up to 821 ng/kg bw
per day. Tea and herbal infusions were by far the main average contributors to the total exposure to
PAs. Among consumers only, in the adult population, the mean chronic exposure via the consumption
of honey ranged between 0.1 and 7.4 ng/kg bw per day (minimum LB–maximum UB), while for high
consumers, it was between 0.4 and 18 ng/kg bw per day (minimum LB–maximum UB). In the young
population, for the average consumers of honey, estimates were between 0.3 and 27 ng/kg bw per
day (minimum LB–maximum UB), and between 0.7 and 31 ng/kg bw per day (minimum LB–maximum
UB) among the high consumers. Ad hoc exposure scenarios for food supplements via consumption of
pollen-based supplements showed chronic exposure to PAs that ranged between 0.7 and 12 ng/kg bw
per day (minimum LB–maximum UB), while acute exposure was between 2.8 and 44 ng/kg bw per
day (minimum LB–maximum UB), in both cases among consumers only. Likewise, the consumption of
150 mL infusion of 2 g of selected plant extracts led to exposures to PAs up to 890 ng/kg bw per day
(e.g. infusion of Borage).
Following initial discussions on appropriate risk management measures to ensure a high level of
human health protection, it was found appropriate to ask EFSA to assess the health risks related to the
estimated exposures to PAs from honey, tea, herbal infusions and food supplements. Furthermore the
CONTAM Panel is requested to provide an opinion on the PAs of relevance in honey, tea, herbal infusions
and food supplements and other feed and food, based on the availability of new occurrence data.
1 EFSA Panel on Contaminants in the Food Chain (CONTAM); Scientiﬁc Opinion on Pyrrolizidine alkaloids in food and feed. EFSA
Journal 2011; 9(11):2406, 134 pp. https://doi.org/10.2903/j.efsa.2011.2406. Available online: www.efsa.europa.eu/efsajournal
2 EFSA (European Food Safety Authority), 2016. Dietary exposure assessment to pyrrolizidine alkaloids in the European
population. EFSA Journal 2016;14(8):4572, 50 pp. https://doi.org/10.2903/j.efsa.2016.4572
3 LB = Lower bound and UB = Upper bound. At the LB, results below the limit of quantiﬁcation (LOQ) and limit of detection
(LOD) were replaced by zero; at the UB, the results below the LOD were replaced by the LOD and those below the LOQ were
replaced by the value reported as LOQ.
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1.1.2. Terms of Reference
In accordance with Art. 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the
European Food Safety Authority (EFSA) to assess the human health risks related to the estimated
exposures to PAs from honey, tea, herbal infusions and food supplements.
Furthermore the CONTAM Panel is requested to provide an opinion on the PAs of relevance in
honey, tea, herbal infusions, food supplements and other feed and food, based on the availability of
new occurrence data.
1.2. Interpretation of the Terms of Reference
EFSA received a request from the European Commission to assess the human health risks related
to the exposure to PAs from honey, tea, herbal infusions and food supplements estimated in a recent
EFSA Technical Report (EFSA, 2016). In addition, an opinion on the PAs of relevance in the
aforementioned foods and other feed and food on the basis of the new available occurrence data was
requested.
The CONTAM Panel concluded that the EC request can be addressed by a Panel statement
including:
• An update of the risk characterisation for human health, considering the new exposure levels
estimated by EFSA
• An analysis of the available data sets on the occurrence of PAs in food and feed to recommend
a list of PAs of relevance for monitoring in food and feed
The CONTAM Panel concluded that a systematic update of the hazard identiﬁcation and
characterisation performed in the previous opinion (EFSA CONTAM Panel, 2011) was not necessary,
also considering the ongoing systematic review under ﬁnalisation by the Joint FAO/WHO Expert
Committee on Food Additives (JECFA), cfr. Summary Report of the Eightieth JECFA meeting (FAO/WHO,
2015). However, the CONTAM Panel noted that an update of the benchmark dose (BMD) modelling
approach applied in the previous opinion is warranted, in view of the new guidance of the EFSA
Scientiﬁc Committee on the use of BMD in risk assessment (EFSA Scientiﬁc Committee, 2017).
1.3. Additional information
Pyrrolizidine alkaloids are a large group of natural toxins synthesised as secondary metabolites by
different plant species. Several PAs are known to be highly toxic to humans and animals as a result of
their presence in the food chain. In 2011, the CONTAM Panel evaluated the risks to human and animal
health related to the presence of PAs in food and feed (EFSA CONTAM Panel, 2011).
PAs can be described as a combination of pyrrolizidine-derived moieties (deﬁned as necine bases)
with a pool of different mono- or dicarboxylic acids (deﬁned as necic acids). In particular, the PAs with
a double bond in position 1,2 of the pyrrolizidine ring system (1,2-unsaturated PAs) are considered of
higher toxicity due to their potential to undergo metabolic activation and form reactive pyrrole species,
which can readily react with proteins and form DNA adducts. An in-depth description of the chemistry
and biochemistry of PAs is present in the previous CONTAM opinion (EFSA CONTAM Panel, 2011).
The toxicity of PAs in humans is documented in a series of case reports of intoxication following
ingestion of PA containing herbal medicines and teas, and outbreak cases including deaths associated
with the consumption of grain contaminated with PA containing weeds. Short-term toxicity of PAs
includes liver and lung as the main target organs, and in particular it is associated with the onset of
hepatic veno-occlusive disease (HVOD). Although most PAs have not been extensively tested in
experimental animals or in vitro systems, information on the tested PAs includes hepatotoxicity,
developmental toxicity, genotoxicity and carcinogenicity. In particular, 1,2-unsaturated PAs are
considered as genotoxic and carcinogenic substances due to their potential to undergo metabolic
activation into reactive pyrroles. Based on available data, the International Agency for Research on
Cancer (IARC) classiﬁed lasiocarpine, monocrotaline and riddelliine as being possibly carcinogenic to
humans (category 2B), while other PAs assessed were not classiﬁable (category 3) due to the limited
information available (IARC 1983, 1987, 2002).
1.3.1. Conclusions of the previous opinion of the CONTAM Panel
In 2011, the CONTAM Panel performed a comprehensive risk assessment for the presence of PAs in
food and feed considering the information available at the time.
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The CONTAM Panel assessed both chronic and acute risks related to the human dietary exposure to
PAs. For the chronic effects, the Panel concluded that all 1,2-unsaturated PAs share a common
metabolic pathway leading to the formation of genotoxic and carcinogenic reactive pyrroles. The
Panel carried out a dose–response analysis for the incidence of liver tumours observed in rodents for
two PAs tested in carcinogenicity studies by the National Toxicology Programme (NTP), lasiocarpine
and riddelliine. A BMDL10 for excess cancer risk of 70 lg/kg bw per day for induction of liver
haemangiosarcomas by lasiocarpine in male rats was selected as the RP for the assessment of chronic
risks and applied in a MOE approach. In view of the lack of long-term studies for other
1,2-unsaturated PAs, the CONTAM Panel assumed a carcinogenic potency equal to lasiocarpine. This
was considered as a conservative approach since lasiocarpine was among the more toxic PAs when
comparing intraperitoneal (i.p.) and intravenous (i.v.) acute LD50s, and toxicity of PAs is considered to
inﬂuence their carcinogenic potency.
The risks related to the possible adverse effect of acute exposure to PAs were assessed considering
the available human data. While the CONTAM Panel could not set an acute reference dose (ARfD), the
limited information available from human poisoning cases allowed identifying a lowest known dose of
approximately 2 mg/kg bw per day associated with acute/short-term effects. This was based on a case
of a 6-month-old girl who received a daily dose of approximately 0.8–1.7 mg PA/kg bw for 2 weeks
and was diagnosed for HVOD, and a 2-month-old boy who was administered an approximate dose of
3 mg/kg bw for 4 days, with a fatal outcome.
The dietary exposure assessment of the CONTAM Panel 2011 opinion was limited to honey as
occurrence data were only available for this food product. Using occurrence data on 14 and 17 PAs
from two independent data sets submitted to EFSA, with eight PAs in common between the two data
sets, the CONTAM Panel estimated dietary exposure for the consumption of retail honey and for honey
purchased locally from a single source. For retail honey, chronic exposure levels up to 37.4 ng/kg bw
per day and 9.03 ng/kg bw per day were estimated for children and adults (mean consumption in
honey consumers only), respectively. Chronic exposure up to 77.8 ng/kg bw per day and 26 ng/kg bw
per day were estimated for 95th percentile consumption in children and adults, respectively. Acute
exposure levels up to 254 ng/kg bw and 110 ng/kg bw were estimated considering the 95th PAs
concentrations and 95th single day consumption for children and adults, respectively. The exposure
estimates calculated in the scenario of honey produced locally from a single source were in general
about 50–100% higher than the results of the calculations for retail honey.
In relation to PAs in retail honey, the calculated MOEs for adults (all consumers) ranged from
3,500,000 to 57,000, and from > 7,000,000 to 7,400, at the mean and high (95th percentile) long-term
consumption, respectively. For ‘toddlers’ (all consumers), the MOEs ranged between 7,000,000 and
14,000, and between 7,000,000 and 1,200 for mean and high (95th percentile) long-term consumption,
respectively. In the scenarios for consumers only, MOEs for adults were in the range 700,000–7,800 and
230,000–2,700 for mean and 95th percentile consumption, respectively. For ‘toddlers’, MOEs ranged
from 175,000 to 1,900 and from 66,000 to 900 for mean and 95th percentile consumption, respectively.
Estimated exposure levels for ‘other children’ were intermediate between those of ‘toddlers’ and adults,
with corresponding MOEs for all consumers in the ranges of 1,800,000–25,000 and > 7,000,000–3,900
at mean and 95th percentile consumption, respectively. Overall, the Panel concluded that there was a
possible health concern for those toddlers and children who are high consumers of honey. Estimates of
acute dietary exposure to PAs in honey were four orders of magnitude lower than the lowest known
PA dose associated with acute/short-term toxicity in humans, indicating no risk of PA acute toxicity
related to consumption of honey. The Panel noted that much higher exposure levels to PAs could
result from pollen and herbal dietary supplements than dietary exposure from honey, but data were
not available for the CONTAM Panel to perform exposure assessments or risk characterisation for these
sources.
For the risk to animal health related to the presence of PAs in feed, no quantitative risk assessment
was possible in view of the limited data on occurrence and toxicity of PAs in livestock and domestic
animals. Exposure to PAs may occur via the consumption of forage and roughage, or herbs and herbal
mixtures contaminated with PA producing plants (e.g. Senecioneae and Boraginaceae spp.). All animal
species were considered sensitive to the toxic effects of PAs, with small ruminants and rabbits being
more resistant than other species. Overall, the CONTAM Panel concluded that the risk of PA poisoning
in the European Union (EU) appears to be low and most poisoning cases reported have been due to
accidental exposure.
Finally, the CONTAM Panel identiﬁed also PAs of particular importance for food and feed,
considering the prominent alkaloids present in the main known PA containing plants. This list was
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subsequently taken forward by the European Commission in a recommendation for monitoring PAs in
food (SCOFCAH, 2014), although it was noted at the time that analytical standards were available only
for some of the PAs listed in EFSA opinion.
1.3.2. Conclusions of the EFSA scientiﬁc report on exposure assessment to PAs
in food
Following a Commission request, EFSA published in August 2016 a scientiﬁc report on the dietary
exposure to PAs through the consumption of honey, tea, herbal infusions (herbs) and food
supplements (EFSA, 2016).
The scientiﬁc report considered the 28 PAs provisionally selected by the European Commission,
based on the EFSA opinion (EFSA CONTAM Panel, 2011) and two reports, one EFSA external Scientiﬁc
report (Mulder et al., 2015) and the other produced by the German Federal Institute for Risk
Assessment (BfR, 2013). Initially, 274,632 analytical results were available for the exposure
estimations; the concentration of PAs in each food sample was estimated adding up all the individual
levels of PAs analysed. For tea and herbal infusions, samples with a minimum of 17 and a maximum of
28 analysed PAs were selected to estimate dietary exposure, while for honey, the number of PAs per
sample in the ﬁnal data set varied between 8 and 19.
Retail honey contained PA concentrations of 14.5–27.5 lg/kg (lower bound–upper bound (LB–UB)).
The ﬁnal data set of tea and herbal infusions contained samples of, among others, ‘Tea and herbs for
infusions, unspeciﬁed’ (n = 1,002), ‘Black tea, infusion’ (n = 339), ‘Green tea, infusion’ (n = 310),
‘Camomile ﬂowers’ (n = 256), Peppermint (n = 196) and ‘Rooibos’ (n = 167). The highest average
concentrations of PAs (expressed as consumed) were found in the samples of rooibos (LB = 4.1 lg/L)
and peppermint (LB = 3.5 lg g/L). Concentrations of PAs in black tea were twice as high as reported
for green tea (LB = 1.6 lg/L and LB = 0.8 lg/L, respectively). Certain food supplements contained
very high levels of PAs. Average PA concentrations of 235–253 lg/kg (LB–UB) were reported for
pollen-based supplements. Much higher concentrations were reported for some plant extracts
consumed as infusions such as borage (Borago ofﬁcinalis) with levels up to 31,101 lg/kg or for
comfrey (Symphytum ofﬁcinale) (up to 29,694 lg/kg), both concentrations expressed in the dry
product. Some supplements containing plant material and sold as capsules/tablets to be directly
ingested possessed the highest levels of PAs (hemp-agrimony (Eupatorium cannabinum) up to
2,400 mg/kg).
In order to cover the whole range of concentrations of PAs reported for tea and herbal infusions,
the estimation of dietary exposure to PAs considered two different scenarios. Together with the other
food commodities, a ﬁrst scenario considered the samples of tea and herbal infusions submitted by
national authorities and those collected through an EFSA Article 36 grant (Scenario A), while a second
scenario assessed exposure based on samples of tea and herbal infusions submitted by Tea & Herbal
Infusions Europe (THIE) (Scenario B).
In the Scenario A, the highest estimates of mean chronic dietary exposure were rather similar in
both the youngest age classes (‘Infants’ and ‘Toddlers’) and the oldest age classes (‘Elderly’, ‘Very
elderly’). In ‘Toddlers’ the maximum exposure estimate was 34.5–48.4 ng/kg bw per day (LB–UB)
while for ‘Very elderly’ was 31.1–41.8 ng/kg bw per day (LB–UB). In the highly exposed population
(95th percentile), the highest estimates were 153.8–214.0 ng/kg bw per day and 87.7–127.2 ng/kg bw
per day (LB–UB) in ‘Toddlers’ and ‘Elderly’–’Very Elderly’, respectively.
In Scenario B, the estimates of chronic exposure were lower as compared to the previous scenario.
Overall, in ‘Infants’ and ‘Toddlers’, the main average contributors were either ‘Tea, unspeciﬁed’ or ‘Tea
and herbs for infusions, unspeciﬁed’. In the adult population, the main contributor to the exposure to
PAs was tea; either reported as ‘Tea, unspeciﬁed’ or as ‘Black tea, infusion’.
Considering the relatively high levels of PAs in honey and its possible regular consumption by
particular subgroups of the population, an ad hoc exposure scenario was applied to estimate the
exposure amongst consumers only. In the adult population, the mean chronic exposure via the
consumption of honey, among consumers only, ranged between 0.1 and 7.4 ng/kg bw per day
(minimum LB–maximum UB), while for high consumers (95th percentile exposure) it was between 9.3
and 17.6 ng/kg bw per day (minimum LB–maximum UB). In the young population, for the average
consumers, estimates ranged between 0.3 and 27.0 ng/kg bw per day (minimum LB–maximum UB),
and between 0.7 and 31.1 ng/kg bw per day (minimum LB–maximum UB) among the high consumers.
Although based on very limited number of eating occasions (n = 32), chronic exposure to PAs via the
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consumption of pollen-based supplements was also estimated and ranged between 0.7 and 11.5 ng/kg
bw per day among consumers only (minimum LB–maximum UB).
Acute dietary exposure to PAs was estimated following a conservative approach considering the
presence of high contamination levels in all the different food commodities combined with the total
daily consumption for each corresponding food (consuming days only). The highest estimates of acute
mean and high (95th percentile) exposure were calculated for ‘Toddlers’, being up to 311 ng/kg bw
per day and up to 821 ng/kg bw per day, respectively. Likewise, the consumption of 150 mL infusion
of 2 g of certain plant extracts with relatively high PA levels can lead to exposure to PAs up to 890 ng/kg
bw per day as estimated for one infusion of borage (B. ofﬁcinalis). For pollen-based supplements, the
acute exposure was between 2.8 and 43.9 ng/kg bw per day (minimum LB–maximum UB), among
consumers only.
On estimating dietary exposure to PAs, the UB levels were highly inﬂuenced by the sensitivity of the
analytical methods and the large proportion of left-censored data. This was particular evident in the
Scenario B, where 93% of the analytical data were left-censored, with almost 60% of the samples of
tea and herbal infusions with not a single PA quantiﬁed. Based on the current sensitivity of the
reported analytical methods for the 28 PAs, the lowest UB concentration that can be achieved for tea
and herbal infusions is 33.5 lg/kg (0.45 lg/L). This would correspond to mean chronic exposure UB
levels (across age groups) up to 3.9–13.5 ng/kg bw per day, and up to 9.5–18.2 ng/kg bw per day
among the highly exposed consumers, depending on the tea and herbal infusion consumed. For
honey, the lowest UB concentration that could be reported with the eight selected PAs all at levels
below the limit of quantiﬁcation (LOQ) would be 3 lg/kg. This would lead to mean chronic exposure
estimations up to 2.9 ng/kg bw per day, and up to 3.4 ng/kg bw per day among the highly exposed
consumers.
In addition to continue ongoing efforts to collect analytical data on the occurrence of PAs in
relevant foods, there is a need to develop more sensitive analytical methods allowing the reduction in
UB levels, and deﬁne performance criteria for the analysis of the most relevant PAs in food.
2. Assessment
2.1. Updated dose–response analysis
The CONTAM Panel agreed that an update of the dose response analysis performed for the chronic
effects of PAs in the previous opinion is warranted in view of the updated guidance of the EFSA
Scientiﬁc Committee on the use of benchmark modelling in risk assessment (EFSA Scientiﬁc
Committee, 2017).
The CONTAM Panel reviewed the dose–response analysis carried out in 2011, brieﬂy described in
Section 1.3.1 of this statement and applied the BMD model averaging approach on the data sets on
the incidence of liver haemangiosarcoma in male and female rats exposed to lasiocarpine (NTP, 1978)
and riddelliine (NTP, 2003). When analysing the data sets, the CONTAM Panel noted that weaknesses
are present in both studies in relation to the application of the BMD approach.
The NTP (1978) study on lasiocarpine reports that 24 rats/sex were tested in each treatment
group, a relatively low number of animals considering the population size currently recommended for
long-term studies in widely accepted test guideline documents. In addition, high mortality was
observed at an early stage of the exposure period in both males and females exposed to the highest
tested dose (1.5 mg/kg bw per day), and to a lesser extent the mid tested dose (0.75 mg/kg bw per
day). In particular, in males an increased mortality started after week 60 and no rats in the high-dose
group survived beyond week 88. Mortality affected more severely the study in female rats, with all
animals in the high dose group dying approximately between week 30 and week 68. The impact of
early mortality on the incidence of liver haemangiosarcoma was evident in female rats and hindered
the possibility to perform BMD analysis on that data set. The Panel noted that early mortality could
have also affected the likelihood of observing tumours in males exposed to 1.5 mg lasiocarpine/kg bw
per day. Finally, the CONTAM Panel noted that the data set has limitations for the performance of BMD
modelling, since all the three tested doses were associated with an increased incidence in liver
haemangiosarcoma higher than the default benchmark response (BMR) of 10%.
The study on riddelliine was conducted with an adequate number of animals per dose group,
following a tailored study design with six female groups (control and ﬁve riddelliine doses) and only
two male groups (control and high dose). Also, in this case, early mortality was observed at the top
dose (0.714 mg/kg bw per day), however, compared to lasiocarpine, a higher incidence of liver
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haemangiosarcoma was observed in both sexes exposed to this high dose (76% and 86% for female
and male rats, respectively), suggesting a low impact of the early mortality in the observed dose–
response relationship. Even though the study design was particularly suitable for the performance of
BMD modelling, the data set on the incidence of liver haemangiosarcoma in female rats was
considered by the CONTAM Panel to have limitations as only the highest tested dose induced a
statistically signiﬁcant increase in tumour incidence. No tumour incidence was observed in the control
group and in the lower three doses ranging from 0.007 to 0.071 mg/kg bw per day. The increased
incidence in liver haemangiosarcoma observed at 0.236 mg/kg bw per day (3 female rats out of 50),
although not achieving statistical signiﬁcance, was considered of biological signiﬁcance in view of the
low spontaneous incidence of this type of tumour in rats (Zwicker et al., 1995).
The BMD modelling of the incidence of liver haemangiosarcoma in male rats exposed to lasiocarpine
and in female rats exposed to riddelliine led to BMD10 conﬁdence intervals (CIs) (BMDL10–BMDU10) of
8–343 and 237–548 lg/kg bw per day, respectively, based on model averaging.
Applying model averaging, the BMD10 CI for lasiocarpine was affected by a high degree of
uncertainty, with a BMDU10 to BMDL10 ratio of about 40-folds and BMDL10–BMDU10 intervals below the
tested dose range for all the accepted individual models. On the other hand, the BMD modelling for
riddelliine using model averaging resulted in a narrower BMDL10–BMDU10 interval, fully included within
the two higher tested doses (equivalent to 237–714 lg/kg bw per day), despite the relatively high
uncertainty related to the poor information on the dose response relationship of the study.
Despite the marked difference between the BMDL10 for lasiocarpine and riddelliine, mainly due to
the aforementioned limitations of the two data sets, a partial overlap of the BMDL10–BMDU10 CIs
calculated using model averaging was observed, suggesting that the two substances could have similar
carcinogenic potency. This was more evident when a BMR falling within the tested dose ranges for both
substances, such as 30%, was selected. BMD30 of 491 and 435 lg/kg bw per day were calculated for
lasiocarpine and riddelliine, respectively, using model averaging. The respective BMDL30–BMDU30
intervals were 211–811 lg/kg bw per day for lasiocarpine and 373–622 lg/kg bw per day for
riddelliine. Overall, this additional modelling supported the assumption that the two PAs can be
considered of similar carcinogenic potency.
In conclusion, the CONTAM Panel selected the BMDL10 of 237 lg/kg bw per day, derived for the
incidence of liver haemangiosarcoma in female rats exposed to riddelliine as RP for the chronic risk
assessment of PAs. Considering the general degree of uncertainty related to the available studies used
for the dose response analysis and the fact that both riddelliine and lasiocarpine are classiﬁed among
the most potent PAs, the CONTAM Panel concluded that the change in the RP maintains the
conservative nature of the previous risk assessment.
The full details of the BMD modelling are given in Appendices A and B.
2.2. Updated risk characterisation
The CONTAM Panel considered that the recent report on dietary exposure assessment to PAs in the
European population (EFSA, 2016), and the updated RP for the assessment of carcinogenicity
warranted the update of the conclusions on the risks to human health of the previous scientiﬁc
opinion.
Chronic risks
With regard to the chronic exposure, the CONTAM Panel applied an MOE approach considering the
different chronic exposure scenarios presented in the latest exposure assessment, using the chronic RP
of 237 lg/kg bw per day for the sum of 1,2-unsaturated PAs assuming equal potency. The EFSA
Scientiﬁc Committee concluded that, for substances that are both genotoxic and carcinogenic, an MOE
of 10,000 or higher, based on a BMDL10 from an animal study, and taking into account overall
uncertainties in the interpretation, would be of low concern from a public health point of view (EFSA,
2005).
Considering the all consumers scenario using the MS and Art 36 occurrence data sets (Scenario A
described in Section 1.3.2), the Panel calculated MOEs ranging from > 10,000,000 to about 4,900 (min
LB–max UB across dietary surveys and age classes) for the mean exposure in the younger age classes
(infants–adolescents) and from > 1,000,000 to 5,700 (min LB–max UB across dietary surveys and age
classes) for adults, as shown in Table 1.
The CONTAM Panel noted that MOEs calculated for all age groups when considering the maximum
LB exposure levels are similar to respective MOEs at the maximum UB, indicating that the differences
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in consumption data present in the various surveys, rather than the analytical uncertainties in the
occurrence data, are mainly responsible of the high variability observed in the minimum LB–maximum
UB MOEs.
When considering the 95th percentile exposure levels calculated in Scenario A, MOEs below 10,000
were calculated for all age groups both at the maximum LB and maximum UB. For the younger age
classes MOEs ranged from > 10,000,000 to about 1,100 (min LB–max UB across dietary surveys and
age classes), and for adults from > 200,000 to about 1,900 (min LB–max UB across dietary surveys
and age classes). The median LB–UB 95th percentile ranged from about 16,200 (median LB in
‘adolescents’) to about 4,200 (median UB in ‘toddlers’) (see Table 1).
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Table 1: Exposure levels calculated in the EFSA report on dietary exposure assessment to pyrrolizidine alkaloids (PAs) (EFSA, 2016), considering data
submitted by EU Member States and from an Article 36 Grant project (Mulder et al., 2015) and related Margin of Exposure (MOEs) using the
Reference Point of 237 lg/kg bw per day for the sum of all 1,2-unsaturated PAs
Mean dietary exposure (ng/kg bw per day) MOEs Mean dietary exposure
Lower bound(a) Upper bound(a) Lower bound Upper boundAge class
N Min Median Max Min Median Max Min Median Max Min Median Max
Infants 6 0 4.1 30.2 0 5.9 42.8 > 1,000,000 57,805 7,848 > 1,000,000 40,169 5,537
Toddlers 10 0 3.2 34.5 0 5.2 48.4 > 1,000,000 74,063 6,870 > 1,000,000 45,577 4,897
Other children 18 0.7 4.2 24.1 1.2 6.4 34.3 338,571 56,429 9,834 197,500 37,031 6,910
Adolescents 17 0.3 3.7 18.4 0.6 5.7 26.1 790,000 64,054 12,880 395,000 41,579 9,080
Adults 17 0.2 6.7 21.3 0.4 10.6 28.8 1,185,000 35,373 11,127 592,500 22,358 8,229
Elderly 14 3.0 8.1 29.5 4.3 12.4 39.9 79,000 29,259 8,034 55,116 19,113 5,940
Very elderly 12 3.9 9.2 31.1 5.7 13.9 41.8 60,769 25,761 7,621 41,579 17,050 5,670
95th percentile dietary exposure(b) (ng/kg bw per day) MOEs 95th percentile dietary exposure
Lower bound(a) Upper bound(a) Lower bound Upper boundAge class
N Min Median Max Min Median Max Min Median Max Min Median Max
Infants 5 0 –(c) 133.6 0 –(c) 185.2 > 10,000,000 1,774 > 10,000,000 1,280
Toddlers 7 0 42.8 153.8 0 57.1 214 > 10,000,000 5,537 1,541 > 10,000,000 4,151 1,107
Other children 18 3.3 21.2 90.5 6.3 32.5 125.6 71,818 11,179 2,619 37,619 7,292 1,887
Adolescents 17 0.8 14.6 68.4 2.4 24.6 95.1 296,250 16,233 3,465 98,750 9,634 2,492
Adults 17 1.1 30.1 85.7 2.0 42.9 120.0 215,455 7,874 2,765 118,500 5,524 1,975
Elderly 14 15.3 33.8 87.7 21.4 52.7 123.3 15,490 7,012 2,702 11,075 4,497 1,922
Very elderly 9 15.9 30.8 86.7 22.9 42.8 127.2 14,906 7,695 2,734 10,349 5,537 1,863
bw: body weight.
(a): Estimates were rounded to one decimal ﬁgure.
(b): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically robust (EFSA, 2011). Those estimates were not included in this
table.
(c): A minimum number of six dietary surveys is required to estimate a statistically robust median (EFSA, 2011).
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The second all consumers chronic scenario was run using the occurrence data set for tea and herbal
infusion submitted by THIE (Scenario B in Section 1.3.2). This led to consistently lower exposure
estimates compared to the previous scenario, and consequently to higher MOEs. This is reﬂected in
particular in the mean exposure scenario, in which MOEs calculated using maximum UB exposure levels
were slightly below 10,000 for ‘infants’ and ‘toddlers’ (approximately around 8,000–9,000), higher than
10,000 for ‘adolescents’ and ‘adults’ (13,100 and 10,500, respectively) and below 10,000 for ‘elderly’
and ‘very elderly’ (7,500 and 7,100, respectively). Maximum UB MOEs calculated for the 95th percentile
consumption were consistently below 10,000 for all age groups (ranging approximately from 1,800 to
3,700). A greater difference was observed for MOEs calculated using LB exposure estimates, reﬂecting
the possible limitations of this data set identiﬁed in the dietary exposure assessment report, including a
lower number of analysed PAs in some samples and a lower analytical sensitivity (EFSA, 2016) (see
Appendix C, Table C.1).
Finally the chronic exposure was estimated for consumers only (see Appendix C, Table C.2),
considering different types of teas, herbal infusions and honey. In particular, for Scenario A, minimum
LB–maximum UB MOEs calculated for the means for only consumers of unspeciﬁed herbs and infusions
ranged from > 1,000,000 to 4,300 and from > 1,000,000 to 1,000 for the adult and young population,
respectively. The 95th percentile MOEs ranged from 395,000 to 1,500 and from 43,000 to 770 for the
adult and young population, respectively. When looking at speciﬁc types of infusions, lower MOEs were
calculated for the consumption of camomile ﬂowers in particular in the young population (minimum
LB–maximum UB approximately at 28,200–5,300 for mean consumption, 95th percentile not
calculated), and for rooibos leaves both for adults (ranges of 21,500–5700 and 7,200–2,100 for mean
and 95th percentile consumption, respectively) and the young population (range of 17,700–2,900,
mean consumption, 95th percentile not calculated). A similar trend to the one reported in the
scenarios on all consumers was observed when calculating MOEs for only consumers in Scenario B
(data not shown).
MOEs calculated for adult consumers only of retail honey ranged between > 1,000,000 and 32,000
(minimum LB–maximum UB) and between 593,000 and 13,500 for mean and 95th percentile
consumption, respectively. For the young population, MOEs ranged from 790,000 to 8,800, and from
339,000 to 7,600 for mean and 95th percentile consumption, respectively.
Regarding the interpretation of the calculated MOEs, the CONTAM Panel noted that a substantial
degree of uncertainty remains in relation to the assumption that all 1,2-unsaturated PAs share the
same mode of action and have carcinogenic potencies equal to the one selected for the establishment
of the RP for neoplastic effects, riddelliine. While it is plausible to assume that following systemic
absorption all 1,2-unsaturated PAs will generate the reactive pyrrole species likely responsible of the
adverse effects, a large variability in toxicokinetic and toxicodynamic can be also expected in view of
the large structural diversity in this group of substances, which could result in a marked variability in
the carcinogenic potency of the individual PAs. In a recent work, Merz and Schrenk (2016) proposed
provisional potency factors for a series of 1,2-unsaturated PAs, based on available data on i.p. and i.v.
acute LD50s in rat and mouse, genotoxic potency in Drosophila melanogaster, and in vitro cytotoxicity
data in a model of chicken hepatocytes. From the analysis of this composite data set, the authors
proposed a rationale to differentiate carcinogenic potency of 1,2-unsaturated PAs, based on the
structure and stereochemistry of their necic acid moieties. In particular, cyclic diesters and
open-chained diesters with 7S conﬁguration (e.g. lasiocarpine, riddelliine or senecionine) were
assigned a relative potency factor (RPF) of 1; monoesters with 7S conﬁguration (e.g. heliotrine) were
assigned RPF of 0.3; and ﬁnally open-chained diesters with 7R conﬁguration (e.g. echimidine) and
7R-monoesters (e.g. intermedine or lycopsamine) were assigned RPF values of 0.1 and 0.01,
respectively. In a more recent approach, Chen et al. (2017) proposed to derive RPFs for a series of
PAs for which information on tumour incidence following exposure in rats is available. Beside the two
PAs with available oral carcinogenicity studies (lasiocarpine and riddelliine), this series includes
monocrotaline, clivorine, senkirkine and symphytine, for which limited information is available on their
carcinogenic potency. Namely, these substances were studied in tests with design limitations (only one
dose group and a control group, limited number of animals and non-standard exposure regime,
including shorter durations and treatment frequencies). In addition, only the study on clivorine was
carried out using the oral route of exposure, whereas i.p. injection was used in the studies on
senkirkine and symphytine, and s.c. injection for monocrotaline. Chen et al. (2017) derived RPFs by
estimating the doses associated with an increase of 10% in tumour incidence (T10) for monocrotaline,
clivorine, senkirkine and symphytine and comparing them with the RP derived by EFSA in 2011 for
lasiocarpine. In the case of riddelliine, the lowest BMDL10 calculated by EFSA in 2011 was selected for
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the comparison. This resulted in RPFs of 1, 0.39, 0.05, 0.23, 0.03 and 0.02 for lasiocarpine, riddelliine,
monocrotaline, clivorine, senkirkine and symphytine, respectively. Finally, in a comparative 28-day oral
toxicity study recently performed by Daleﬁeld et al. (2016) on echimidine and lasiocarpine, Wistar rats
(10/sex per dose) were exposed to either one of these two PAs at doses of 0.6, 1.2 or 2.5 mg/kg bw,
including a common negative control group. A signiﬁcant decrease in body weight gain was observed
in male and female rats treated with lasiocarpine at ≥ 1.2 and 2.5 mg/kg bw per day, respectively,
while no effects on body weight gain were observed in the groups treated with echimidine. No other
adverse effects were observed for the two substances. The CONTAM Panel concluded that, due to the
limitations in the analysed data set and the provisional nature of the semi-quantitative approach
proposed by Merz and Schrenk (2016), it is not adequate to use the derived RPFs for the cumulative
risk assessment of PAs in food. Similarly, the approach proposed by Chen et al. (2017) has also
important limitations and its use is not considered adequate for the risk assessment of PAs. However,
altogether these publications suggest that several of the PAs mainly contributing to the dietary
exposure levels calculated in the EFSA report (2016) could be of substantially lower potency than
riddelliine or lasiocarpine. As already discussed in the 2011 opinion, The CONTAM Panel therefore
conﬁrmed the conservative nature of the RP based on potent PAs such as riddelliine or lasiocarpine for
the cumulative risk assessment of PAs in food.
The CONTAM Panel concluded that the MOEs calculated for all consumers in the mean and high
(95th percentile) consumption scenarios indicate a possible concern for human health. In particular a
concern was expressed for frequent and high consumers of teas or herbal infusions.
Acute risks
As described in Section 1.3.1, an approximate lowest known dose of 2 mg PA/kg bw per day
associated with acute/short-term toxicity in humans was used by the CONTAM Panel for the
assessment of acute risks, based on information from human cases indicating short-term toxicity
following exposure in the range 1–3 mg PA/kg bw per day for periods ranging from 4 days up to
2 weeks.
In the 2016 EFSA report, acute dietary exposure to PAs was estimated considering the presence of
high contamination levels in all the different food commodities, combined with the total daily
consumption for each corresponding food. This conservative approach resulted in acute exposure
levels ranging from approximately 1 to 300 ng/kg bw per day and from 6 to 170 ng/kg bw per day for
mean consumers in the younger age classes (infants–adolescents) and adults, respectively. Exposure
for the 95th percentile consumption levels was well below 1 lg/kg bw per day in all age classes. In
view of the margin of more than three orders of magnitude between the estimated exposure levels
and the lowest known dose range of 1–3 mg PA/kg bw per day at which human acute/short-term
toxicity has been reported, the CONTAM Panel concluded that there is a low risk related to acute
dietary exposure to PAs through the consumption of teas, herbal infusions and honey.
In speciﬁc scenarios, the acute (or short-term, assuming daily consumption of the same food
supplement batch for few days/weeks) exposure to PAs related to the consumption of food
supplements was estimated. In the 2016 dietary exposure report of EFSA, a wide range of PA
concentrations was reported for herbal food supplements, reaching total PA levels of more than 2 g/kg
in some samples. Acute/short-term exposure was estimated for plant extracts intended to be
consumed following infusion (by assuming the same dilution factor used for teas and herbal infusions)
or to be ingested as capsules/tablets. A single consumption occasion of a B. ofﬁcinalis infusion led to
an estimated acute/short-term exposure of 890 ng/kg bw per day. In another scenario, ingestion of
one tablet/capsule of boneset (Eupatorium perfoliatum) or hemp-agrimony (E. cannabinum)
corresponded to estimated acute/short-term exposure levels of about 800–1,800 lg/kg bw per day,
respectively. Acute/short-term exposure through the consumption of pollen-based supplements showed
much lower exposure estimates in the range of 3–44 ng/kg bw per day.
The CONTAM Panel concluded that the consumption of herbal food supplements based on
PA-producing plants could reach acute/short-term exposure levels in the range of doses associated
with severe acute/short-term effects in humans. This is supported by a series of human cases of
intoxication following the consumption of herbal remedies derived from PA-producing plants (EFSA
CONTAM Panel, 2011). In view of the uncertainty on the possible toxicity levels of PAs in humans and
of the severity of the effects, the CONTAM Panel concluded that exposure levels less than 100 times
lower than the aforementioned dose range of 1–3 mg PA/kg bw per day may be associated with the
risk of acute/short-term effects.
Consumption of pollen-based supplements is not considered to pose acute risks to human health.
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2.3. Recommended PAs for monitoring in food and feed
2.3.1. Food
Together with the estimation of the dietary exposure to PAs in the European population, the 2016
EFSA scientiﬁc report carried out an exhaustive evaluation of the available occurrence data in diverse
food commodities, including the contribution of each PAs to the total contamination levels in the
samples (EFSA, 2016).
Considering the ﬁnal data set of tea and herbal infusions, the main average contributors to the total PA
concentration in green tea were senecionine-N-oxide (19%), retrorsine-N-oxide (18%), and intermedine
and lycopsamine, both with 16% contribution. In black tea, the main contributors, on average, were
intermedine-N-oxide (31%), intermedine (20%), lycopsamine (20%) and retrorsine-N-oxide (15%); in
camomile, senecionine-N-oxide (28%), intermedine (22%), senecionine and lycopsamine (both 10%); in
peppermint, seneciphylline-N-oxide (28%), senecionine-N-oxide (25%), retrorsine-N-oxide (13%) and
seneciphylline (11%); and in rooibos, senecionine-N-oxide (57%), retrorsine-N-oxide (19%) and
senecionine (16%).
Overall, among the samples of tea and herbal infusions, the main contributors to the total PA
concentration were, on average: lycopsamine, intermedine, intermedine-N-oxide, senecionine,
senecionine-N-oxide, seneciphylline, seneciphylline-N-oxide and retrorsine-N-oxide. In black tea, these
eight PAs represented, on average, 95% of the total PA concentration, 92% in samples of rooibos,
90% in samples of camomile, 83% in samples of peppermint and 78% in green tea.
Among the samples of retail honey, the main contributors to the total PA concentration in each
sample were, on average, echimidine (44%) and lycopsamine (37%). Similar main contributors had
been already described for the 1,324 samples available in the 2011 CONTAM opinion that were also
part of the 1,966 samples used in the 2016 EFSA scientiﬁc report.
For food supplements (plant extracts and pollen-based supplements) overall, the highest average
contributions to the total PA levels came from lycopsamine, intermedine and their N-oxides. An
exception was the samples of coltsfoot, where 80–90% of the total concentration of PAs came from
senkirkine.
Together with their occurrence in the different food commodities, other criteria such as the
toxicology and chromatographic separation were also considered when selecting a set of PAs to be
monitored.
From an analytical point of view, the analysis of certain PA isomers such as intermedine/lycopsamine
or senecionine/senecivernine as well as their N-oxide derivatives present certain difﬁculties. It is
reported that by using high-performance liquid chromatography–tandem mass spectrometry (HPLC–
MS/MS), the most habitual analytical method for the analysis of PAs, a baseline chromatographic
separation is not always achieved for these PAs (Crews, 2013). In addition, they have the same
molecular weight and cannot be distinguished by mass spectrometry. Due to this fact, it seems
that an accurate quantiﬁcation of the individual PAs is not always possible. For the pair
intermedine/lycopsamine also co-elution of indicine could happen (Mulder et al., 2015). An identical
situation is observed for indicine-N-oxide and the N-oxide derivatives of intermedine/lycopsamine.
Another issue to be considered is that the ratio between the two forms usually present, the PA-N-oxide
(PANO) and the free tertiary base, strongly depends of many factors among them the sample
preparation and extraction conditions (EFSA CONTAM Panel, 2011). Therefore, a general
recommendation is to analyse both forms regardless of the PAs selected.
Other PAs that should be monitored, although not relevant in terms to their contribution to the
total occurrence in the current data set, are lasiocarpine and senkirkine. Lasiocarpine is among the
most toxic of the PAs that have been tested, and the BMDL10 for induction of liver haemangiosarcomas
in male rats was used as RP in the previous EFSA opinion (EFSA CONTAM Panel, 2011). In addition,
and although lasiocarpine was only quantiﬁed in less than 5% of the samples analysed, in certain food
categories in particular in ‘Tea for infants and young children’, this PA represented on average 42% of
the total concentration among the samples where it was analysed. Regarding, senkirkine, its average
contribution to the occurrence levels in the food commodities (honey and tea/herbal infusions) was
negligible (e.g. 0.9% in honey and 1.7% in green tea). However, senkirkine can be of particular
importance in certain plant extracts, such as Tussilago farfara (coltsfoot), samples with reported PA
levels above 400 lg/L and with this PA contributing to 80–90% of the total concentration.
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Based on this information, the CONTAM Panel proposed a set of 17 PAs to be monitored in food:
intermedine/lycopsamine, intermedine-N-oxide/lycopsamine-N-oxide, senecionine/senecivernine, senecionine-
N-oxide/senecivernine-N-oxide, seneciphylline, seneciphylline-N-oxide, retrorsine, retrorsine-N-oxide,
echimidine, echimidine-N-oxide, lasiocarpine, lasiocarpine-N-oxide and senkirkine. When considering
this list, it should be taken into account that diverse PAs may co-elute with some of the PAs included.
This is the case for instance of indicine and indicine-N-oxide that, however, are not relevant PAs in
food. Under certain analytical conditions, these compounds may not be completely separate from the
pair intermedine/lycopsamine and their respective N-oxides.
In addition to the proposed 17 PAs, recent analyses of tea samples (personal communication, Dr. Patrick
Mulder, RIKILT) seem to indicate that other PAs could also have a relevant contribution to the levels of PAs in
different foods. This refers mainly to integerrimine and echinatine together with their N-oxides which
are not always chromatographically separated to baseline from the pairs senecionine-N-oxide/
senecivernine-N-oxide and intermedine-N-oxide/lycopsamine-N-oxide, respectively. While echinatine is a
structural isomer of lycopsamine and intermedine being a relevant PA in Eupatorium and Cynoglossum
species, integerrimine has been described in T. farfara and Senecio vulgaris plants (El-Shazly and Wink,
2014; Nedelcheva et al., 2015).
Therefore, and based on standard availability, PAs other than those included in the proposed list of
17 PAs should be also monitored to better understand the occurrence of PAs in food.
Following the approach used in the 2016 EFSA scientiﬁc report (EFSA, 2016), an hypothetical
scenario was built to assess what would be the dietary exposure in the European population if all
results were below LOQ, based on the performance of current analytical methods for PAs (as provided
in Table 12 of the 2016 EFSA scientiﬁc report). Estimates of dietary exposure to PAs were calculated
assuming that all 17 PAs from the proposed list were below the LOQ, summing the 17 LOQs and
combining the resulting value with the consumption of different food commodities (consumers only).
Among the young population (‘Infants’, ‘Toddlers’ and ‘Other children’), the maximum mean dietary
exposure was estimated for ‘Tea and herbs for infusions, unspeciﬁed’ being 7.5 ng/kg bw per day, and
a maximum 95th exposure of 10.1 ng/kg bw per day in the same food commodity. In the adult
population (‘Adults’, ‘Elderly’ and ‘Very elderly’) highest mean exposure was estimated with the
consumption of ‘Tea and herbs for infusions, unspeciﬁed’ being 5.2 ng/kg bw per day, while the
maximum 95th exposure was estimated via the consumption of ‘Tea unspeciﬁed, decaffeinated’ to be
5.3 ng/kg bw per day. More details for the different food commodities and the range of chronic
exposure estimates across the different dietary surveys is given in Appendix D. It can be noted that
the application of the MOE approach to the exposure estimates reported in Appendix D and using the
chronic RP of 237 lg/kg bw per day for the sum of 1,2-unsaturated PAs assuming equal potency,
would result in MOEs above 10,000.
2.3.2. Feed
A total of 29,739 analytical results were available on different PAs, for a total of 524 samples.
Samples were collected between 2006 and 2016, with 438 samples collected in the Netherlands and
86 in the Czech Republic. As compared to the situation at the moment of the publication of the 2011
CONTAM opinion, only few more samples (173) were available, 87 collected in the Netherlands and 86
in the Czech Republic. Samples collected in the Czech Republic were analysed for either four PAs
(retrorsine, seneciphylline, senecionine and senkirkine, 37 samples) or ﬁve PAs (same PAs as
before + monocrotaline, 49 samples).
All the samples collected in the Netherlands were analysed for 67 PAs, including 26 out of the 28
PAs provisionally selected by the European Commission (individual results for intermedine and its N-
oxide were not reported). Following a clariﬁcation request to the data provider, it was conﬁrmed that
the analytical method was not able, at that time, to distinguish between intermedine/lycopsamine and
intermedine-N-oxide/lycopsamine-N-oxide so the results were reported as lycopsamine and
lycopsamine-N-oxide.
All samples from the Czech Republic were left-censored data; Table 2, therefore, shows the levels
of PAs reported only for the samples collected in the Netherlands. Feed samples were classiﬁed
according to the Catalogue of feed materials as described in Commission Regulation (EU) No 68/20134.
4 Commission Regulation (EU) No 68/2013 of 16 January 2013 on the Catalogue of feed materials. OJ L 29, 30.1.2013, p. 1–64.
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The list of the 67 PAs analysed in the samples collected in the Netherlands is shown in Table 3.
The sensitivity of the method (liquid chromatography with tandem mass spectrometry (LC–MS/MS))
was 4.5 lg/kg for all PAs, expressed as limit of detection (LOD). Out of the 438 feed samples, at least
one PA was reported for 209 samples.
Regarding the 28 PAs that belong to the list provisionally selected by the European Commission,
they were quantiﬁed at 803 occasions (7%), with seneciphylline (n = 129) and seneciphylline-N-oxide
(n = 103), reported the most. For the 41 PAs that are not part of the Commission list, they were
quantiﬁed in 579 occasions (3%) in 143 different samples. Among those quantiﬁed the most often
occurring were: integerrimine (n = 66), integerrimine-N-oxide (n = 60), spartioidine (n = 60),
spartioidine-N-oxide (n = 47), iso-acetylechimidine (n = 40), iso-echimidine (n = 41), riddelliine
(n = 39) and riddelliine-N-oxide (n = 35).
Table 2: Mean values of PAs reported for different types of feed samples collected in the
Netherlands
N
Number
of LC
Mean concentration
(lg/kg)
Lower
bound
Middle
bound
Upper
bound
Cereal grains, their products
and by-products
Wheat 1 0 23 171 320
Maize 4 4 0 151 302
Millet 4 4 0 151 302
Oats 1 1 0 151 302
Rice, broken 3 3 0 151 302
Sorghum; [Milo] 2 2 0 151 302
Oil seeds, oil fruits, and
products derived thereof
Palm kernel expeller 4 4 0 151 302
Rape seed 4 1 9 159 308
Toasted soya (beans) 46 37 3 153 303
Sunﬂower seed 6 5 5 155 305
Linseed 11 6 30 177 325
Legume seeds and products
derived thereof
Peas 7 6 16 166 315
Carob, dried 2 1 8 156 305
Sweet lupins 4 4 0 151 302
Tubers, roots, and products
derived thereof
Carrots 1 1 0 151 302
Other seeds and fruits, and
products derived thereof
Other seeds and fruits,
and products derived
thereof
2 1 22 169 316
Citrus pulp 3 2 12 161 311
Forages and roughage, and
products derived thereof
Lucerne, alfalfa 149 18 368 503 637
Grass, ﬁeld dried, hay 152 117 174 322 470
Other plants, algae and
products derived thereof
Other plants, algae and
products derived thereof
32 12 290 435 580
N: Number of samples; LC: left-censored (samples with no PAs quantiﬁed).
The concentration in each sample was derived by summing the concentrations reported for each of the 67 PAs analysed.
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Table 3: List of PAs analysed in samples collected in the Netherlands
Acetylheliosupine Acetylheliosupine-N-oxide Acetylechinatine Acetylechinatine-N-oxide Acetylerucifoline Acetylerucifoline-N-oxide
Acetylseneciphylline Acetylseneciphylline-N-oxide Acetyllycopsamine Acetyllycopsamine-N-oxide Acetylechimidine Acetylechimidine-N-oxide
Doronine Desacetyldoronine Dehydrojaconine Echinatine Echinatine-N-oxide Echimidine
Echimidine-N-oxide Echiumine Echiumine-N-oxide Europine Europine-N-oxide Erucifoline
Erucifoline-N-oxide Florosenine Floridanine Heliotrine Heliotrine-N-oxide Heliosupine
Heliosupine-N-oxide Heleurine-N-oxide Integerrimine Integerrimine-N-oxide Jacobine Jacobine-N-oxide
Jacoline Jacoline-N-oxide Jaconine Jaconine-N-oxide Jacozine Jacozine-N-oxide
Lasiocarpine Lasiocarpine-N-oxide Monocrotaline Monocrotaline-N-oxide Lycopsamine Lycopsamine-N-oxide
Otosenine Onetine Retrorsine Retrorsine-N-oxide Riddelliine Riddelliine-N-oxide
Senecionine Senecionine-N-oxide Senecivernine Senecivernine-N-oxide Spartioidine Seneciphylline
Seneciphylline-N-oxide Senkirkine Spartioidine-N-oxide Trichodesmine Trichodesmine-N-oxide Usuramine
Usaramine-N-oxide
Those PAs included among the 28 provisionally selected by the European Commission are in bold (intermedine/lycopsamine and intermedine-N-oxide/lycopsamine-N-oxide were reported as
lycopsamine and lycopsamine-N-oxide, respectively, as they were not resolved by the analytical method used).
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Some further assessments for the contribution of the different analysed PAs were focused on the
two feed categories best represented: ‘Lucerne (alfalfa)’ and ‘Grass, ﬁeld dried (hay)’, since they were
the only feed groups with a relatively high number of samples quantiﬁed (n = 131 and n = 35,
respectively). The feed group ‘Other plants, algae and products derived thereof’ (n = 32) covered a
very heterogeneous number of samples, with seventeen different types of plants and six samples
reported as ‘Herbal mix’ without further information. In most of the cases, only one or two samples
were available for each type of plant, making any interpretation either on the PA levels or on the
proﬁle of PAs reported difﬁcult (see Table 4).
Grass, hay
In a total of 35 samples among the 152 analysed, at least one PA was quantiﬁed (23%). In almost
half of these samples (17), the PAs from the Commission list represented 100% of the total
concentration, while in 10 samples (29%) they represented below 60% of the total. On average, the
PAs from the European Commission list represent 78% of the PA levels reported in hay. When looking
at the potential contribution of the 17 PAs suggested to be monitored in food, the average
contribution in the 35 samples was 69% of the total, in 15 samples representing 100%.
There was one sample where none of the PAs from the Commission list was quantiﬁed; the only
PAs quantiﬁed was acetylerucifoline-N-oxide. Overall, the other 41 PAs were identiﬁed in total in 88
occasions (18 samples), with no PA standing up among the others in number of occasions reported as
quantiﬁed (acetylerucifoline, n = 6).
Lucerne, alfalfa
In a total of 131 samples among the 149 analysed, at least one PA was quantiﬁed (88%). In 26
samples (20%), the PAs from the Commission list represented 100% of the total concentration, while
in only 32 (24%) they represented less than 60% of the total (Table 5). On average, the PAs from
the Commission list represented 72% of the PA levels reported. In these 32 samples, the most
important PAs outside those from the Commission list were acetylheliosupine and heliosupine that
represented on average 23% and 16% of the total concentration, respectively.
Table 4: Samples of ‘Other plants, algae and products derived thereof’ collected in the Netherlands
Mean concentration (lg/kg)
N
Number
of LC
Lower
bound
Middle
bound
Upper
bound
Other plants, algae and
products derived thereof
Herbal mix 6 0 353 492 630
Herbal mix, artichoke 1 0 2,252 2,385 2,517
Herbal mix, camomile 2 1 35 184 334
Herbal mix, dandelion 2 1 663 793 924
Herbal mix, fennel 2 1 1,592 1,732 1,871
Herbal mix, ginseng 1 0 5 154 302
Herbal mix, goldenrod 2 0 18 165 312
Herbal mix, knotweed 1 0 97 241 385
Herbal mix, leek 1 1 0 151 302
Herbal mix, marigold 1 1 0 151 302
Herbal mix, milk thistle 1 0 12 161 309
Herbal mix, mint 2 2 0 151 302
Herbal mix, nettle 5 3 16 165 314
Herbal mix, oregano 1 0 89 235 381
Herbal mix, parsley 1 1 0 151 302
Herbal mix, rose hip 1 1 0 151 302
Herbal mix, rosemary 1 0 5 154 302
Herbal mix, verbena 1 0 18 164 310
N: Number of samples; LC: left-censored (samples with no PAs quantiﬁed).
The concentration in each sample was derived by summing the concentrations reported for each of the 67 PAs analysed.
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Concerning the list of 17 PAs suggested to be monitored in food, they represented, on average,
68% of the total PA levels, in 23 of the samples representing 100% and in another 70 samples above
60%.
Overall, the 41 PAs not on the European Commission list were quantiﬁed in 449 occasions (118
samples); those that were more often reported as quantiﬁed were integerrimine (n = 58), spartioidine
(n = 55) and integerrimine-N-oxide (n = 52). It is also worth mentioning that riddelliine and riddelliine-
N-oxide were reported as quantiﬁed in 34 and 32 occasions, respectively (Table 6).
Table 5: Presence of the PAs from the Commission list in different samples of ‘Lucerne, alfalfa’ and
‘Grass, ﬁeld dried (hay)’) quantiﬁed for at least for one PA
Lucerne; (alfalfa) Grass, ﬁeld dried, (hay)
N(a)
Contribution
N(a)
Contribution
Quantiﬁed(b) Average Max Quantiﬁed(b) Average Max
Echimidine 131 1 0.1 14.0 35 0 0.0 0.0
Echimidine-N-oxide 131 6 1.0 86.0 35 1 0.0 0.1
Europine 131 0 0.0 0.0 35 0 0.0 0.0
Europine-N-oxide 131 0 0.0 0.0 35 0 0.0 0.0
Heliotrine 131 0 0.0 0.0 35 0 0.0 0.0
Heliotrine-N-oxide 131 0 0.0 0.0 35 0 0.0 0.0
Erucifoline 131 10 0.3 25.7 35 8 2.3 25.7
Erucifoline-N-oxide 131 6 0.8 100.0 35 5 2.5 27.2
Jacobine 131 15 1.6 100.0 35 6 1.8 17.1
Jacobine-N-oxide 131 4 0.8 100.0 35 3 2.5 77.8
Lasiocarpine 131 0 0.0 0.0 35 0 0.0 0.0
Lasiocarpine-N-oxide 131 0 0.0 0.0 35 0 0.0 0.0
Lycopsamine(c) 131 29 2.0 38.5 35 8 5.9 67.3
Lycopsamine-N-oxide(c) 131 10 1.2 100.0 35 8 8.5 100.0
Monocrotaline 131 0 0.0 0.0 35 0 0.0 0.0
Monocrotaline-N-oxide 131 0 0.0 0.0 35 0 0.0 0.0
Retrorsine 131 78 7.3 43.9 35 6 1.4 17.5
Retrorsine-N-oxide 131 71 7.6 43.2 35 8 4.5 100.0
Senecionine 131 81 7.9 100.0 35 8 2.0 15.8
Seneciphylline 131 107 20.1 100.0 35 19 26.3 100.0
Senecionine-N-oxide 131 66 5.2 33.3 35 10 4.7 100.0
Seneciphylline-N-oxide 131 84 13.8 100.0 35 14 15.6 100.0
Senecivernine 131 34 0.8 7.8 35 2 0.1 3.5
Senecivernine-N-oxide 131 19 0.6 11.1 35 0 0.0 0.0
Senkirkine 131 2 0.8 100.0 35 1 0.0 0.5
Trichodesmine 131 0 0.0 0.0 35 0 0.0 0.0
(a): Number of samples with at least one PA quantiﬁed.
(b): Number of times quantiﬁed.
(c): Intermedine/lycopsamine and intermedine-N-oxide/lycopsamine-N-oxide were reported as lycopsamine and lycopsamine-N-
oxide respectively as they were not resolved by the analytical method used.
Table 6: Presence of PAs other than those from the Commission list in different samples of
‘Lucerne, alfalfa’ and ‘Grass, ﬁeld dried (hay)’) quantiﬁed for at least for one PA
Lucerne; (alfalfa) Grass, ﬁeld dried, (hay)
N(a)
Contribution
N(a)
Contribution
Quantiﬁed(b) Average Max Quantiﬁed(b) Average Max
Acetyllycopsamine 131 10 2.2 82.3 35 3 1.0 26.0
Acetyllycopsamine-N-oxide 131 1 0.0 1.5 35 3 0.4 10.1
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Further attention was also paid in highly contaminated samples to the contribution of the PAs
quantiﬁed the highest number of times among the 41 PAs not included in the Commission list. The
focus was put on ‘Lucerne, alfalfa’ where a total of 131 samples were reported with at least one PA
quantiﬁed (see Table 6); among them the 50 samples with the highest levels were selected. In these
samples, heliosupine and, above all, acetylheliosupine contributed signiﬁcantly to the total levels of
PAs. Acetylheliosupine was quantiﬁed in 18 out of these 50 samples, in several occasions with
Lucerne; (alfalfa) Grass, ﬁeld dried, (hay)
N(a)
Contribution
N(a)
Contribution
Quantiﬁed(b) Average Max Quantiﬁed(b) Average Max
Acetylechimidine 131 0 0.0 0.0 35 0 0.0 0.0
Acetylechimidine-N-oxide 131 0 0.0 0.0 35 0 0.0 0.0
Acetylerucifoline 131 4 0.1 5.3 35 6 1.5 40.0
Acetylerucifoline-N-oxide 131 0 0.0 0.0 35 4 3.2 100.0
Acetylseneciphylline 131 1 0.2 22.7 35 1 0.1 3.2
Acetylseneciphylline-N-
oxide
131 0 0.0 0.0 35 1 0.1 5.2
Dehydrojaconine 131 0 0.0 0.0 35 1 0.0 1.2
Desacetyldoronine 131 0 0.0 0.0 35 3 0.3 5.8
Doronine 131 0 0.0 0.0 35 1 0.1 4.8
Echiumine 131 7 0.1 4.7 35 2 0.3 5.5
Echiumine-N-oxide 131 2 0.0 2.5 35 3 2.9 65.7
Floridanine 131 0 0.0 0.0 35 1 0.2 7.0
Florosenine 131 1 0.0 0.4 35 2 0.5 9.2
Heleurine-N-oxide 131 0 0.0 0.0 35 0 0.0 0.0
Integerrimine 131 58 2.5 13.6 35 5 0.5 5.4
Integerrimine-N-oxide 131 52 2.2 20.0 35 4 0.5 8.2
Acetylheliosupine 131 35 6.2 62.7 35 4 2.3 36.0
Acetylheliosupine-N-oxide 131 22 1.3 21.5 35 2 0.6 18.4
Acetylechinatine-N-oxide 131 0 0.0 0.0 35 2 0.1 2.5
Acetylechinatine 131 2 0.0 2.1 35 2 0.2 5.5
Heliosupine 131 32 4.3 50.0 35 5 1.4 20.0
Heliosupine-N-oxide 131 19 1.1 22.2 35 1 0.2 7.8
Echinatine 131 4 0.3 30.6 35 1 0.1 2.5
Echinatine-N-oxide 131 1 0.0 0.7 35 0 0.0 0.0
Jacoline 131 0 0.0 0.0 35 1 0.1 1.8
Jacoline-N-oxide 131 0 0.0 0.0 35 1 0.0 0.7
Jaconine 131 11 0.3 22.7 35 4 1.0 15.2
Jaconine-N-oxide 131 0 0.0 0.0 35 1 0.1 4.2
Jacozine 131 2 0.0 3.4 35 1 0.0 0.2
Jacozine-N-oxide 131 0 0.0 0.0 35 1 0.0 0.4
Onetine 131 0 0.0 0.0 35 2 0.2 8.7
Otosenine 131 1 0.0 0.3 35 3 1.1 20.0
Riddelliine 131 34 1.0 12.2 35 5 0.3 5.8
Riddelliine-N-oxide 131 32 0.9 19.0 35 2 0.1 1.7
Spartioidine 131 55 2.9 21.4 35 4 0.4 9.8
Spartioidine-N-oxide 131 42 2.2 45.2 35 4 2.0 41.7
Trichodesmine-N-oxide 131 0 0.0 0.0 35 0 0.0 0.0
Usaramine-N-oxide 131 10 0.2 9.5 35 1 0.0 0.4
Usuramine 131 12 0.1 2.1 35 1 0.0 0.0
(a): Number of samples with at least one PA quantiﬁed.
(b): Number of times quantiﬁed.
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contribution above 40% (max = 57%); heliosupine was also quantiﬁed in 18 samples, in several with a
contribution above 20% of the total PA levels (max = 27%).
The CONTAM Panel is of the opinion that a very limited number of feed samples are available to
carry out a comprehensive evaluation of the PAs most typically present in feed. Furthermore, they
come from one country and may be locally produced (grass, alfalfa). As a result, speciﬁc weeds
present in these products may not be representative for those growing in other parts of the EU, like in
the South or at higher altitudes. Based on this, it is difﬁcult to conclude on which PAs should be
monitored when analysing feed samples. Overall, a recommendation is given to analyse, at least, the
17 PAs proposed for food. Likewise, and as proposed for food, PAs other than those included in the
proposed list should be also monitored to better understand the occurrence of PAs in feed.
2.4. Uncertainty analysis
Uncertainties associated to the estimates of dietary exposure to PAs have been already described
(EFSA, 2016). In brief, the main uncertainties refer the large proportion of left-censored data, the fact
that not all samples reported analytical data for all 28 PAs, and to the presence of an important
number of both eating occasions and occurrence data on unspeciﬁed tea and herbs for infusions.
Likewise, there is uncertainty on how analytical methods (extraction) represent the different ways
consumers prepare tea and herbal infusions. In addition, the fact that many other PAs, not routinely
monitored or not yet identiﬁed, could also be present in food may lead to an underestimation of the
exposure levels. Overall, the dietary exposure to PAs calculated was likely to overestimate the
exposure levels of the European population.
There are also uncertainties linked to the assessment of the PAs present in feed; the number of
samples was very limited and collected in just one country so they may not be representative
especially considering the role of weeds growing speciﬁcally in certain parts of Europe.
Regarding the hazard characterisation, the CONTAM Panel conﬁrmed the uncertainties already
identiﬁed in the 2011 opinion (EFSA CONTAM Panel, 2011), and noted additional uncertainties in
particular related to the data sets used for the dose–response analysis for the characterisation of the
carcinogenic hazard (see Section 2.1). However, the Panel conﬁrmed that the main uncertainties
remain considering the lack of toxicological data on most of the PAs of relevance for food and feed
contamination. As already concluded in 2011, the CONTAM Panel conﬁrmed that the carcinogenic
potency of many PAs present in food is expected to be lower than the potency of the two PAs with
available long term studies, lasiocarpine and riddelliine. Therefore, basing the cumulative risk
assessment of PAs on an RP derived from riddelliine without correcting for individual potencies is
considered as a conservative approach. In relation to the acute risk assessment, the CONTAM
Panel noted substantial uncertainties in the available human data hindering the possibility to establish
an ARfD.
3. Conclusions
• In view of the updated guidance of the EFSA Scientiﬁc Committee on the use of Benchmark
dose in risk assessment, the CONTAM Panel updated the BMD analysis of the available long-term
studies on lasiocarpine and riddelliine performed in its previous risk assessment. Using model
averaging, the Panel calculated the BMD conﬁdence interval and selected the BMDL10 of
237 lg/kg bw per day for increase in the incidence of liver haemangiosarcoma in female rats
exposed to riddelliine as the RP for chronic risk assessment.
• The CONTAM Panel updated the risk characterisation performed in its scientiﬁc opinion
published in 2011 considering the updated RP and most recent exposure levels calculated in
the EFSA report of 2016 considering data in honey, teas, herbal infusions and food
supplements.
• In line with its previous opinion, considering the genotoxic and carcinogenic nature of PAs, the
CONTAM Panel applied a MOE approach to the cumulative chronic exposure levels of PAs. The
EFSA Scientiﬁc Committee concluded that, for substances that are both genotoxic and
carcinogenic, an MOE of 10,000 or higher, based on a BMDL10 from an animal study, and
taking into account overall uncertainties in the interpretation, would be of low concern from a
public health point of view.
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• MOEs considering chronic mean exposure levels in all consumers ranged from > 10,000,000 to
about 4,900 (min LB–max UB across dietary surveys and age classes) in the younger age
classes and from > 1,000,000 to 5,700 in adults. When considering high (95th percentile)
consumption, MOEs ranged from > 10,000,000 to about 1,100, and from > 200,000 to about
1,900 for the younger and adult age classes, respectively.
• In the case of the chronic mean exposure levels calculated in consumers only of different types
of teas and herbal infusions, MOEs ranged from > 1,000,000 to 4,300 and from > 1,000,000
to 1,000 for the adult and young population, respectively. MOEs calculated at 95th percentile
of consumption ranged from 395,000 to 1,500 and from 43,000 to 770 for the adult and
young population, respectively. Lower MOEs were calculated for the consumption of camomile
ﬂowers in particular in the young population, and for rooibos leaves both for the adult and
young population.
• In the case of the chronic mean exposure levels calculated in consumers only of retail honey,
MOEs ranged between > 1,000,000 and 32,000 and between 593,000 and 13,500 for adults at
mean and 95th percentile consumption, respectively. For the younger groups of the
population, MOEs ranged between 790,000 and 8,800 and between 339,000 and 7,600 for
mean and 95th percentile consumption, respectively.
• Overall, the CONTAM Panel concluded that the MOEs calculated for all consumers in the mean
and high (95th percentile) consumption scenarios indicate a possible concern for human
health. In particular, a concern was expressed for frequent and high consumers of teas or
herbal infusions.
• The CONTAM Panel assessed also the acute/short-term risks, considering the dietary acute
exposure levels estimated in the 2016 EFSA report and the lowest known dose range of
1–3 mg PA/kg bw per day, at which acute/short-term adverse effects have been reported in
humans.
• Acute exposure considering the simultaneous presence of high contamination levels in all the
different food commodities ranged from 1 to 300 ng/kg bw per day and from 6 to 170 ng/kg
bw per day for mean consumers in the younger age classes (infants–adolescents) and adults,
respectively. Exposure for the 95th percentile consumption levels was well below 1 lg/kg bw
per day in all age classes. In view of the margin of more than three orders of magnitude
between these exposure levels and the lowest known dose range associated with human
acute/short-term adverse effects, the CONTAM Panel concluded that there is a low risk related
to acute dietary exposure to PAs through the consumption of teas, herbal infusions and honey.
• Acute or short-term exposure to PAs related to the consumption of food supplements was
estimated to vary considerably depending on the type of supplement. Consumption of PA
producing plant extracts to be consumed following infusion led to exposure levels as high as
890 ng/kg bw per day. Ingestion of one tablet/capsule based on PA-producing plants
corresponded to estimates of acute/short-term exposure levels of about 800 or 1,800 lg/kg
bw per day. Acute/short-term exposure through the consumption of pollen-based supplements
showed much lower exposure estimates in the range of 3–44 ng/kg bw per day.
• The CONTAM Panel concluded that the consumption of herbal food supplements based on
PA-producing plants could reach acute/short-term exposure levels in the range of doses
associated with severe acute/short-term effects in humans. In view of the uncertainty on the
possible toxicity levels of PAs in humans and of the severity of the effects, the CONTAM
Panel concluded that exposure levels less than 100 times lower than the aforementioned dose
range of 1–3 mg PA/kg bw per day may be associated with the risk of acute/short-term
effects.
• Consumption of pollen-based supplements is not considered to pose acute risks to human
health.
• Based on the current data set, the CONTAM Panel proposed a set of 17 PAs to be
monitored in food, namely: intermedine/lycopsamine, intermedine-N-oxide/lycopsamine-N-
oxide, senecionine/senecivernine, senecionine-N-oxide/senecivernine-N-oxide, seneciphylline,
seneciphylline-N-oxide, retrorsine, retrorsine-N-oxide, echimidine, echimidine-N-oxide, lasiocarpine,
lasiocarpine-N-oxide, and senkirkine.
• The CONTAM Panel acknowledged that the number of feed samples was very limited to carry
out a comprehensive evaluation of the PAs most typically present in feed. However, while
expecting to have more representative data in the future, the Panel considered appropriate to
monitor at least the 17 PAs proposed for food also in feed.
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• The list of PAs proposed for monitoring in food and feed is not expected to cover all possible
PAs that may be present in the different commodities, but to include the most relevant PAs
considering both their contribution to the total levels and their possible toxicological potencies.
This approach is expected to facilitate the monitoring of PAs without compromising a high level
of consumer protection.
4. Recommendations
• There is a need for toxicological data relating to the PAs most commonly found in food. In
particular information on the toxicokinetics, metabolic activation and carcinogenic potency of
the individual PAs would allow substantial reﬁnement of the risk assessment.
• Ongoing efforts should continue to collect analytical data on the occurrence of PAs in relevant
food and feed commodities, as well as in herbal food supplements.
• Based on standard availability, PAs other than those included in the proposed list of 17 PAs
should be also monitored to better understand the occurrence of PAs in food and feed.
• More sensitive and selective analytical methods should be developed to assess the presence of
PAs in food and feed and to decrease the uncertainties in the exposure assessment.
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AIC Akaike information criterion
ARfD acute reference dose
bw body weight
BMD benchmark dose
BMDL benchmark dose lower conﬁdence limit
BMDU benchmark dose upper conﬁdence limit
BMR benchmark response
CI conﬁdence interval
CONTAM EFSA Panel on Contaminants in the Food Chain
HPLC–MS/MS high-performance liquid chromatography – tandem mass spectrometry
HVOD hepatic veno-occlusive disease
IARC International Agency for Research on Cancer
i.p. intraperitoneal
i.v. Intravenous
JECFA Joint FAO/WHO Expert Committee on Food Additives and Contaminants
LB lower bound
LC–MS/MS liquid chromatography with tandem mass spectrometry
LD50 lethal dose, median
LOD limit of detection
LOQ limit of quantiﬁcation
MOE Margin of Exposure
NTP National Toxicology Programme
PA pyrrolizidine alkaloids
PANO pyrrolizidine alkaloid-N-oxide
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s.c. subcutaneous
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Appendix A – Benchmark dose modelling of incidence of liver
haemangiosarcoma in male rats exposed to lasiocarpine (NTP, 1978)
A. Data description
As already outlined in the previous EFSA opinion (EFSA CONTAM Panel, 2011), reported
lasiocarpine levels administered in the diet were converted to doses by considering average body
weight and daily food intake of 400 g and 20 g, respectively. This corresponds to the default
conversion factor of 0.05 recommended by the EFSA Scientiﬁc Committee guidance (2012) for chronic
rat studies.
Dose (lg/kg bw per day) Incidence liver haemangiosarcoma N
0 0 23
350 5 24
750 11 23
1,500 13 23
N: number of animals; bw: body weight.
B. Selection of benchmark response
A default benchmark response (BMR) of 10% (extra risk compared with the background risk) and a
two-sided 90% conﬁdence interval of the BMD were selected as recommended by EFSA Scientiﬁc
Committee (2017). Additional calculations were performed applying a BMR of 30% for comparing
carcinogenic potencies of lasiocarpine and riddelliine.
C. Software used and speciﬁcations
• Fitting benchmark dose models was based on the R-package proast61.3.
• Averaging results from multiple ﬁtted benchmark dose models was based on the methodology
in Wheeler and Bailer (2008).
• The default set of ﬁtted models was applied as recommended by EFSA Scientiﬁc Committee
(2017)
• Selection of the BMD conﬁdence interval and the BMDL was carried out following the ﬂow
chart of EFSA Scientiﬁc Committee (2017)
D. Results
Model
Number of
parameters
Log-
likelihood
AIC BMD10
(a) BMDL10
(a) BMDU10
(a) Converged
Accepted
AIC
Null 1 57.71 117.42 NA NA NA Yes
Full 4 43.95 95.90 NA NA NA Yes
Logistic 2 48.17 100.34 392.86 301.85 510.82 Yes No
Probit 2 47.89 99.78 388.11 281.08 489.20 Yes No
Log-
logistic
3 44.25 94.50 134.32 4.81 297.70 Yes Yes
Log-
probit
3 44.23 94.46 151.06 7.36 309.78 Yes Yes
Weibull 3 44.34 94.68 103.34 1.70 271.73 Yes Yes
Gamma 3 44.36 94.72 99.41 0.65 283.22 Yes Yes
Two-
stage
3 44.50 95.00 157.76 117.10 218.95 Yes Yes
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
(a): Results expressed as lg/kg bw per day.
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Logistic Probit
Log-
logistic
Log-
probit
Weibull Gamma Two-stage
Estimated model weights 0.01 0.02 0.21 0.22 0.19 0.19 0.16
Using the parametric bootstrap with a total of 1,000 generated data sets, the BMDL and the BMDU
were the 5th and 95th percentile of all parametric bootstrap BMD values, respectively.
Estimates in lg/kg bw per day based on the model averaging (see EFSA Scientiﬁc Committee,
2017):
When applying a BMR of 30%, the following results were obtained
Model
Number of
parameters
Log-
likelihood
AIC BMD30
(a) BMDL30
(a) BMDU30
(a) Converged
Accepted
AIC
Null 1 57.71 117.42 NA NA NA Yes
Full 4 43.95 95.90 NA NA NA Yes
Logistic 2 48.17 100.34 880.86 711.16 1,166.91 Yes No
Probit 2 47.86 99.72 857.49 698.66 1,153.10 Yes No
Log-
logistic
3 44.25 94.50 470.78 158.26 705.30 Yes Yes
Log-
probit
3 44.23 94.46 470.49 162.65 695.34 Yes Yes
Weibull 3 44.34 94.68 469.42 133.92 726.08 Yes Yes
Gamma 3 44.36 94.72 473.39 119.38 727.37 Yes Yes
Two-
stage
3 44.50 95.00 534.05 396.43 741.21 Yes Yes
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
(a): Results expressed as lg/kg bw per day.
Logistic Probit Log-logistic Log-probit Weibull Gamma Two-stage
Estimated model
weights
0.01 0.02 0.21 0.22 0.19 0.19 0.16
BMD10 BMDL10 BMDU10
131.38 8.34 343.32
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Using the parametric bootstrap with a total of 1,000 generated data sets, the BMDL and the BMDU
were the 5th and 95th percentile of all parametric bootstrap BMD values, respectively.
Estimates in lg/kg bw per day based on the model averaging (see EFSA Scientiﬁc Committee,
2017):
BMD30 BMDL30 BMDU30
490.88 210.5 810.85
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Appendix B – Benchmark dose modelling of incidence of liver
haemangiosarcoma in female rats exposed to riddelliine (NTP, 2003)
A. Data description
As already discussed in the previous EFSA opinion (EFSA CONTAM Panel, 2011), reported riddelliine
doses were corrected by a factor of 5/7 to account for the exposure regime applied in the study
(5 days of exposure per week) were converted to doses by considering average bw and daily food
intake of 400 g and 20 g, respectively. This corresponds to the default conversion factor of 0.05
recommended by the EFSA Scientiﬁc Committee guidance (2012) for chronic rat studies.
Dose (lg/kg bw per day) Incidence liver haemangiosarcoma N
0 0 50
7 0 50
24 0 50
71 0 50
236 3 50
714 38 50
N: number of animals.
B. Selection of benchmark response
A default benchmark response (BMR) of 10% (extra risk compared with the background risk) and a
90% interval around the BMD were selected as recommended by EFSA Scientiﬁc Committee (2017).
Additional calculations were performed applying a BMR of 30% for comparing carcinogenic potencies
of lasiocarpine and riddelliine.
C. Software used and speciﬁcations
• Fitting benchmark dose models was based on the R-package proast61.3.
• Averaging results from multiple ﬁtted benchmark dose models was based on the methodology
in Wheeler and Bailer (2008).
• Default set of ﬁtted models were applied as recommended by EFSA Scientiﬁc Committee
(2017)
• Selection of BMDL was carried out following the ﬂow chart of EFSA Scientiﬁc Committee (2017)
D. Results
Model
Number of
parameters
Log-
likelihood
AIC BMD10
(a) BMDL10
(a) BMDU10
(a) Converged
Accepted
AIC
Null 1 119.66 241.32 NA NA NA Yes
Full 6 38.90 89.80 NA NA NA Yes
Logistic 2 40.32 84.64 362.77 298.90 430.74 Yes Yes
Probit 2 39.63 83.26 327.91 270.55 385.59 Yes Yes
Log-
logistic
3 38.95 83.90 278.32 216.29 345.24 Yes Yes
Log-
probit
3 38.90 83.80 269.90 215.09 323.21 Yes Yes
Weibull 3 39.00 84.00 290.30 218.19 366.26 Yes Yes
Gamma 3 38.92 83.84 277.13 215.62 336.89 Yes Yes
Two-
stage
3 41.12 88.24 207.97 182.26 239.53 No No
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
(a): results expressed as lg/kg bw per day.
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Logistic Probit Log-logistic Log-probit Weibull Gamma
Estimated model weights 0.11 0.23 0.16 0.17 0.16 0.17
Using the parametric bootstrap with a total of 1,000 generated data sets, the BMDL and the BMDU
were the 5th and 95th percentile of all parametric bootstrap BMD values, respectively.
Estimates in lg/kg bw per day based on the model averaging (see EFSA Scientiﬁc Committee,
2017):
When applying a BMR of 30%, the following results were obtained
Model
Number of
parameters
Log-
likelihood
AIC BMD30
(a) BMDL30
(a) BMDU30
(a) Converged
Accepted
AIC
Null 1 119.66 241.32 NA NA NA Yes
Full 6 38.90 89.80 NA NA NA Yes
Logistic 2 40.32 84.64 501.48 447.86 553.76 Yes Yes
Probit 2 39.63 83.26 473.57 423.56 525.77 Yes Yes
Log-
logistic
3 38.95 83.90 406.60 344.26 472.04 Yes Yes
Log-
probit
3 38.90 83.80 390.94 335.64 447.35 Yes Yes
Weibull 3 39.00 84.00 442.09 375.50 506.25 Yes Yes
Gamma 3 38.92 83.84 411.12 353.44 468.78 Yes Yes
Two-
stage
3 41.12 88.24 382.65 335.35 440.72 No No
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
(a): results expressed as lg/kg bw per day.
Logistic Probit Log-logistic Log-probit Weibull Gamma
Estimated model weights 0.11 0.23 0.16 0.17 0.16 0.17
BMD10 BMDL10 BMDU10
292.53 236.58 548.31
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Using the parametric bootstrap with a total of 1,000 generated data sets, the BMDL and the BMDU
were the 5th and 95th percentile of all parametric bootstrap BMD values, respectively.
Estimates in lg/kg bw per day based on the model averaging (see EFSA Scientiﬁc Committee,
2017):
BMD30 BMDL30 BMDU30
434.91 373.01 622.37
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Appendix C – Margin of Exposure tables
Table C.1: All consumers exposure levels calculated in the EFSA report on dietary exposure assessment to pyrrolizidine alkaloids (PAs) (EFSA, 2016),
using occurrence data set from THIE (Scenario B, see Section 1.3.2), and related Margin of Exposure (MOEs) using the Reference Point of
237 lg/kg bw per day for the sum of all 1,2-unsaturated PAs
Mean dietary exposure (ng/kg bw per day) MOEs Mean dietary exposure
Lower bound(a) Upper bound(a) Lower bound Upper boundAge class
N Min Median Max Min Median Max Min Median Max Min Median Max
Infants 6 0.00 0.60 5.50 0.00 3.60 26.60 (> 1,000,000) 395,000 43,091 (> 1,000,000) 65,833 8,910
Toddlers 10 0.00 1.00 6.10 0.00 4.60 29.80 (> 1,000,000) 237,000 38,852 (> 1,000,000) 51,522 7,953
Other children 18 0.20 1.20 4.40 1.00 5.20 23.70 1,185,000 197,500 53,864 237,000 45,577 10,000
Adolescents 17 0.20 0.70 3.40 0.50 4.40 18.10 1,185,000 338,571 69,706 474,000 53,864 13,094
Adults 17 0.10 1.20 3.70 0.40 8.10 22.60 2,370,000 197,500 64,054 592,500 29,259 10,487
Elderly 14 0.70 1.80 5.40 3.40 9.80 31.60 338,571 131,667 43,889 69,706 24,184 7,500
Very elderly 12 0.90 1.80 5.70 4.30 10.90 33.40 263,333 131,667 41,579 55,116 21,743 7,096
95th percentile dietary exposure(b) (ng/kg bw per day) MOEs 95th percentile dietary exposure
Lower bound(a) Upper bound(a) Lower bound Upper boundAge class
N Min Median Max Min Median Max Min Median Max Min Median Max
Infants 5 0.00 –(c) 19.00 0.00 –(c) 106.20 (> 1,000,000) 12,474 (> 1,000,000) 2,232
Toddlers 7 0.00 7.60 23.30 0.00 45.60 131.30 (> 1,000,000) 31,184 10,172 (> 1,000,000) 5,197 1,805
Other children 18 1.30 7.00 14.30 6.30 26.70 77.00 182,308 33,857 16,573 37,619 8,876 3,078
Adolescents 17 0.80 3.70 13.10 2.40 18.50 64.90 296,250 64,054 18,092 98,750 12,811 3,652
Adults 17 0.90 5.40 14.70 1.90 33.70 78.10 263,333 43,889 16,122 124,737 7,033 3,035
Elderly 14 3.00 6.70 14.70 15.90 37.20 78.80 79,000 35,373 16,122 14,906 6,371 3,008
Very elderly 9 4.00 8.20 15.90 18.20 33.90 76.90 59,250 28,902 14,906 13,022 6,991 3,082
bw: body weight.
(a): Estimates were rounded to one decimal ﬁgure.
(b): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may be not statistically robust (EFSA, 2011). Those estimates were not included in the table.
(c): A minimum number of six dietary surveys is required to estimate a statistically robust median (EFSA, 2011).
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Table C.2: Consumers only exposure levels calculated in the EFSA report on dietary exposure assessment to pyrrolizidine alkaloids (PAs) (EFSA, 2016),
using occurrence data set from Article 36 project and EU Member States (Scenario A, see Section 1.3.2), and related Margin of Exposure
(MOEs) using the Reference Point of 237 lg/kg bw per day for the sum of all 1,2-unsaturated PAs
Adult consumers
Mean exposure P95 exposure MOEs (Mean exposure) MOEs (P95 exposure)
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Tea and herbs for
infusions, unspeciﬁed
0.2 39.6 0.2 54.7 0.6 114.4 0.8 158.1 1,185,000 5,985 1,185,000 4,333 395,000 2,072 296,250 1,499
Tea, unspeciﬁed 0.9 22.2 1.5 37 6 53.7 10 89.5 263,333 10,676 158,000 6,405 39,500 4,413 23,700 2,648
Tea unspeciﬁed,
decaffeinated
0.5 2.5 2.3 12.6 6.3 6.3 31.5 31.5 474,000 94,800 103,043 18,810 37,619 37,619 7,524 7,524
Black tea, infusion 1.9 32.2 2.5 42.6 15.9 70.3 21.1 93.1 124,737 7,360 94,800 5,563 14,906 3,371 11,232 2,546
Green tea, infusion 2.4 15.4 4.8 30.7 15.4 41.8 30.7 83.5 98,750 15,390 49,375 7,720 15,390 5,670 7,720 2,838
Camomile ﬂowers 1.9 14.1 2.7 19.6 39.9 39.9 55.7 55.7 124,737 16,809 87,778 12,092 5,940 5,940 4,255 4,255
Peppermint 0.7 34 0.8 42 338,571 6,971 296,250 5,643
Rooibos leaves 11 36 12.6 41.3 32.9 96.4 37.8 110.6 21,545 6,583 18,810 5,738 7,204 2,459 6,270 2,143
Tea for infants and
young children
– – – – – – – – – – – – – – – –
Honey 0.1 3.9 0.3 7.4 0.4 9.3 0.8 17.6 2,370,000 60,769 790,000 32,027 592,500 25,484 296,250 13,466
Young consumers
Mean exposure P95 exposure MOEs (Mean exposure) MOEs (P95 exposure)
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Tea and herbs for
infusions, unspeciﬁed
0.6 165 0.8 228 5.5 222.2 7.6 307 395,000 1,436 296,250 1,039 43,091 1,067 31,184 772
Tea, unspeciﬁed 0.6 33.9 1 56.5 14.7 93 24.5 155 395,000 6,991 237,000 4,195 16,122 2,548 9,673 1,529
Tea unspeciﬁed,
decaffeinated
0.4 2 2.1 9.9 592,500 118,500 112,857 23,939
Black tea, infusion 1.5 41.4 2 54.9 44.4 64.4 58.8 85.3 158,000 5,725 118,500 4,317 5,338 3,680 4,031 2,778
Green tea, infusion 1.2 11.5 2.4 23 197,500 20,609 98,750 10,304
Camomile ﬂowers 8.4 32.3 11.7 45.1 28,214 7,337 20,256 5,255
Peppermint 0.7 29.9 0.8 37 61.9 74.6 338,571 7,926 296,250 6,405 3,829 3,177
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Young consumers
Mean exposure P95 exposure MOEs (Mean exposure) MOEs (P95 exposure)
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Min
LB
Max
LB
Min
UB
Max
UB
Rooibos leaves 13.4 70.2 15.4 80.5 17,687 3,376 15,390 2,944
Tea for infants and
young children
0.2 10.6 0.4 24.8 1,185,000 22,358 592,500 9,556
Honey 0.3 14.2 0.6 27 0.7 16.4 1.4 31.1 790,000 16,690 395,000 8,778 338,571 14,451 169,286 7,621
LB: lower bound; UB: upper bound.
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Appendix D – Hypothetical chronic exposure estimates to PAs across
different dietary surveys considering consumers only
Concentration
of PAs(d)
(lg/kg per lg/L)
Young population(a) Adult population(b)
Mean
exposure
95th
exposure(c)
Mean
exposure
95th
exposure(c)
ng/kg bw per day ng/kg bw per day
Tea and herbs for infusions,
unspeciﬁed
19/0.25 0.03–7.5 0.25–10.1 0.01–1.8 0.03–5.2
Tea unspeciﬁed 19/0.25 0.05–2.8 1.2–7.8 0.08–1.9 0.5–4.5
Tea unspeciﬁed,
decaffeinated
19/0.25 0.35–1.7 – 0.38–2.1 5.3
Black tea, infusion 19/0.25 0.10–2.8 3.0–4.4 0.13–2.2 1.08–4.8
Green tea, infusion 19/0.25 0.13–1.2 – 0.25–1.6 1.60–4.4
Camomile ﬂowers 19/0.25 0.55–2.1 – 0.13–0.9 2.6
Peppermint 19/0.25 0.03–1.1 2.3 0.03–1.3 –
Rooibos leaves 19/0.25 0.55–2.9 – 0.45–1.5 1.35–4.0
Tea for infants and young
children
19/0.25 0.08–4.4 – – –
PA: pyrrolizidine alkaloid; bw: body weight.
(a): Young population comprises the age classes ‘Infants’, ‘Toddlers’ and ‘Other children’ across the different dietary surveys.
(b): Adult population comprises the age classes ‘Adults’, ‘Elderly’ and ‘Very elderly’ across the different dietary surveys.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011). Those estimates were not included in this table.
(d): Hypothetical concentration of PAs assuming that the 17 selected PAs were all left-censored data and the analytical method
used reported the lowest LOQs as provided in Table 12 of the 2016 EFSA scientiﬁc report on dietary exposure to PAs. Levels
in lg/L for tea/herbal infusions are obtained using 2 g of dry product in 150 mL of water.
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